T1  ClinicalConsequencePK 0 68  % Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)
T2  ClinicalConsequencePK 272 275   AUC
T3  DrugIndividual 70 89    AED Co-administered
T4  DrugIndividual 91 109   AED Coadministered
T5  ClinicalConsequencePK 111 128   AED Concentration
T6  DrugIndividual 593 600  Alcohol
T7  ClinicalConsequencePK 485 488   AUC
T8  ManagementOption 578 591    Adjusted Dose
T9  DrugIndividual 602 615  Alpha-Blocker
T10 DrugIndividual 617 627  Analgesics
T11 DrugIndividual 641 661  Anti-coagulant drugs
T12 DrugIndividual 663 679  Antiarrhythmics:
T13 DrugIndividual 717 728  Antibiotics
T14 ClinicalConsequencePK 277 310   AUC ofCoadministeredDrug (95% CI)
T15 ClinicalConsequencePK 312 344   AUC ofCoadministeredDrug(90% CI)
T16 ClinicalConsequencePK 346 369   AUC ofDidanosine(90% CI
T17 ClinicalConsequencePK 373 396   UC ofDidanosine(95% CI)
T18 ClinicalConsequencePK 398 422   AUC ofStavudine (95% CI)
T19 ClinicalConsequencePK 462 465   AUC
T20 DrugIndividual 730 741  Antibiotics
T22 ClinicalConsequencePK 793 807   Anticoagulants
T23 DrugIndividual 933 948  Anticonvulsants
T24 DrugIndividual 968 989  Antiretroviral agents
T25 DrugIndividual 991 1006 Antiretrovirals
T26 DrugGroup 1009 1023 enzodiazapines
T27 DrugGroup 1025 1038 Beta-Blockers
T28 ClinicalConsequenceOther 1040 1058  CLINICAL EFFECT(S)
T29 DrugIndividual 1088 1105    CONCOMITANT  DRUG
T30 DrugGroup 1107 1136 Caffeine/Xanthine Derivatives
T31 DrugGroup 1158 1198 Central Nervous System (CNS) Depressants
T32 DrugGroup 1200 1216 Classes of Drugs
T33 ContextualInformation 1253 1269 Clinical Comment
T21 DrugGroup 777 791   Anticoagulants
T34 ClinicalConsequenceOther 1291 1305  linical Impact
T35 ClinicalConsequencePK 1437 1441 Cmax
T36 ClinicalConsequenceOther 1308 1329  Clinical Implications
T37 ManagementOption 1385 1408  Clinical Recommendation
T38 ClinicalConsequencePK 1354 1383 Magnitude of Drug Interaction
T39 Mechanism 1331 1349 Clinical Rationale
T40 ClinicalConsequencePK 1443 1478 Cmax SS (Peak plasma concentration)
T41 ClinicalConsequencePK 1480 1514 Cmax ofCoadministeredDrug (95% CI)
T42 ClinicalConsequencePK 1516 1549 Cmax ofCoadministeredDrug(90% CI)
#1  AnnotatorNotes T10  heading title is a drug group but refers to individual drugs in subgroup
#2  AnnotatorNotes T11  heading title is a drug group but refers to individual drugs in subgroup
#3  AnnotatorNotes T12  heading title is a drug group but refers to individual drugs in subgroup
#4  AnnotatorNotes T13  heading title is a drug group but refers to individual drugs in subgroup
#5  AnnotatorNotes T20  heading title is a drug group but refers to individual drugs in subgroup
#6  AnnotatorNotes T21  heading title is a drug group, refers to its derivatives
#7  AnnotatorNotes T23  heading title is a drug group but refers to individual drugs in subgroup
#8  AnnotatorNotes T24  heading title is a drug group but refers to individual drugs in subgroup
#9  AnnotatorNotes T25  heading title is a drug group but refers to individual drugs in subgroup
T43 ClinicalConsequencePK 1551 1576 Cmax ofDidanosine(90% CI)
T44 ClinicalConsequencePK 1578 1603 Cmax ofDidanosine(95% CI)
T45 ClinicalConsequencePK 1644 1669 Cmax of Stavudine(95% CI)
T46 ClinicalConsequencePK 1671 1675 Cmax
T47 ClinicalConsequencePK 1727 1730 min
T48 ClinicalConsequencePK 1719 1723 Cmax
T49 DrugIndividual 1732 1752    Co-administered Drug
T50 ManagementOption 1754 1789  Co-administered Drug Dose (Schedule
T51 ContextualInformation 1901 1909 Comments
T52 DrugGroup 1929 1959 Concomitant Drug Class or Food
T53 DrugGroup 1961 1983 Concomitant Drug Class
T54 DrugIndividual 1985 1994    Drug Name
T55 DrugGroup 2030 2052 Concomitant Drug Class
T56 DrugIndividual 2053 2067    Specific Drugs
T57 DrugGroup 2069 2104 Concomitant Drug Name or Drug Class
T58 ClinicalConsequencePK 2143 2163 Conjugated Estrogens
T59 ClinicalConsequencePK 2165 2210 Conjugated Estrogens plus PROMETRIUM Capsules
T60 DrugGroup 2261 2276 Corticosteroids
T61 DrugGroup 2278 2290 Cyclosporine
T62 ClinicalConsequenceOther 2292 2318  DESCRIPTION OF INTERACTION
T63 ManagementOption 2348 2365  Didanosine Dosage
T64 ContextualInformation 2385 2392 Diluent
T65 ManagementOption 2394 2427  Dosage Adjustment of Aripiprazole
T66 ManagementOption 2503 2507  Dose
T67 ManagementOption 2524 2528  Dose
T68 ManagementOption 2547 2550  ose
T69 ClinicalConsequencePK 2569 2573 Dose
T70 ManagementOption 2725 2740  Dosing Schedule
T71 ManagementOption 2701 2723  Dosing Recommendations
T72 DrugGroup 2783 2793 Drug Class
T73 DrugGroup 2795 2805 Drug Class
T74 DrugIndividual 2807 2816    Drug Name
T75 DrugIndividual 3032 3041    Drug Name
T76 ContextualInformation 2818 2893 Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis
#10 AnnotatorNotes T76  table title
T77 ClinicalConsequencePK 3056 3076 Drug Plasma Exposure
T78 DrugGroup 3151 3158 Drug(s)
#11 AnnotatorNotes T78  lists both individual drugs and drug groups
T79 DrugGroup 3139 3149 Drug Class
T80 DrugIndividual 3131 3135    Drug
T81 DrugGroup 3160 3206 Drug(s) Affecting Pharmacokinetics of CIPRO XR
#12 AnnotatorNotes T81  also includes some individual drugs
T82 DrugGroup 3208 3272 Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Tablets, USP
#13 AnnotatorNotes T82  also includes some individual drugs
T83 DrugGroup 3274 3321 Drug(s) with Pharmacokinetics Affected by KETEK
#14 AnnotatorNotes T83  also includes some individual drugs
T84 Mechanism 3322 3346 Mechanism of interaction
T85 DrugIndividual 3359 3363    Drug
T86 DrugGroup 3364 3374 Drug Class
T87 Mechanism 3375 3399 Mechanism of Interaction
T88 DrugIndividual 3418 3422    Drug
T89 DrugGroup 3423 3433 Drug Class
T90 Mechanism 3434 3458 Mechanism of Interaction
T91 ContextualInformation 3585 3619 Drugs Known to Prolong QT Interval
T92 DrugIndividual 3621 3653    Drugs That Are Affected By KETEK
T93 ContextualInformation 3655 3691 Drugs That Interfere with Hemostasis
T94 DrugGroup 3693 3707 Drugs That May
T95 DrugGroup 3743 3766 Drugs That are Affected
#15 AnnotatorNotes T95  also provides management options
T96 DrugGroup 3777 3800 Drugs That are Affected
#16 AnnotatorNotes T96  also provides management options
T97 DrugGroup 3814 3837 Drugs That are Affected
#17 AnnotatorNotes T97  also provides management options
T98 DrugGroup 3856 3909 Drugs That are Affected by Ciprofloxacin Tablets, USP
#18 AnnotatorNotes T98  also provides management options
T99 Mechanism 3911 3945 Drugs known to prolong QT interval
T100    ClinicalConsequencePK 8296 8304 Mean AUC
T101    ClinicalConsequencePK 8306 8315 Mean Cmax
T102    DrugGroup 4002 4018 Drugs that alter
T103    DrugGroup 4046 4066 Drugs that may alter
#19 AnnotatorNotes T103 also includes some individual drugs
T104    DrugGroup 4091 4111 Drugs that may alter
#20 AnnotatorNotes T104 also includes some individual drugs
T105    DrugGroup 4271 4291 Drugs that may alter
#21 AnnotatorNotes T105 also includes some individual drugs
T106    DrugGroup 4404 4418 Drugs that may
#22 AnnotatorNotes T106 also includes some individual drugs
T107    DrugGroup 4460 4474 Drugs that may
#23 AnnotatorNotes T107 also includes some individual drugs
T108    DrugGroup 4485 4498 Drugs that ma
#24 AnnotatorNotes T108 also includes some individual drugs
T109    DrugGroup 4539 4553 Drugs that may
#25 AnnotatorNotes T109 also includes some individual drugs
T110    DrugGroup 4741 4755 Drugs that may
#26 AnnotatorNotes T110 also includes some individual drugs
T111    DrugGroup 4790 4804 Drugs that may
#27 AnnotatorNotes T111 also includes some individual drugs
T112    DrugGroup 4963 4977 Drugs that may
#28 AnnotatorNotes T112 also includes some individual drugs
T113    DrugGroup 4988 5002 Drugs that may
#29 AnnotatorNotes T113 also includes some individual drugs
T114    DrugGroup 5146 5160 Drugs that may
#30 AnnotatorNotes T114 also includes some individual drugs
T115    DrugGroup 5195 5209 Drugs that may
#31 AnnotatorNotes T115 also includes some individual drugs
T116    DrugGroup 5370 5384 Drugs that may
#32 AnnotatorNotes T116 also includes some individual drugs
T117    DrugGroup 5703 5733 Drugs with a known interaction
#33 AnnotatorNotes T117 also includes some individual drugs
T118    DrugGroup 5890 5895 Drugs
#34 AnnotatorNotes T118 also includes some individual drugs
T119    ClinicalConsequenceOther 5898 5904  EFFECT
T120    ClinicalConsequencePK 5914 5937 Effect on Active Moiety
T121    ClinicalConsequencePK 6084 6107 Effect on Concentration
T122    ClinicalConsequencePK 6109 6132 Effect on Concentration
T123    ClinicalConsequencePK 6168 6191 Effect on Concentration
T124    ClinicalConsequencePK 6227 6250 Effect on Concentration
T125    ClinicalConsequencePK 6287 6310 Effect on Concentration
T126    ClinicalConsequencePK 6346 6369 Effect on Concentration
T127    ClinicalConsequencePK 6406 6429 Effect on Concentration
T128    ClinicalConsequencePK 6614 6636 Effect onConcentration
T129    DrugIndividual 7013 7019    Enzyme
#35 AnnotatorNotes T129 lists different CYP inhibitors
T130    DrugIndividual 7021 7047    Enzyme (CYP2D6) Inhibitors
T131    DrugIndividual 7133 7158    Enzyme (CYP3A) Inhibitors
T132    DrugIndividual 7186 7223    Enzyme (CYP3A/ PgP inducers) Inducers
T133    FrequencyExposure 7225 7233 Exposure
T134    ContextualInformation 7235 7242 Factors
T135    DrugIndividual 7269 7284    Glucocorticoids
T136    DrugIndividual 7286 7306    HIV Antiviral Agents
T137    DrugIndividual 7308 7328    HIV Antiviral Agents
T138    DrugIndividual 7388 7408    HIV Antiviral Agents
T139    DrugIndividual 7437 7459    HIV-1-Antiviral Agents
T140    DrugIndividual 7514 7542    Hepatitis C Antiviral Agents
T141    DrugIndividual 7576 7584    Inducers
T142    ClinicalConsequencePK 7586 7661 Influence of AED on MHD Concentration(Mean Change, 90% Confidence Interval)
T143    ClinicalConsequencePK 7663 7748 Influence of Oxcarbazepine on AED Concentration(Mean Change, 90% Confidence Interval)
T144    DrugIndividual 7750 7760    Inhibitors
T145    DrugIndividual 7762 7780    Interacting Agents
T146    DrugIndividual 7782 7798    Interacting Drug
T147    Mechanism 7935 7946 Interaction
T148    ContextualInformation 8004 8034 Known CYP2D6 Poor Metabolizers
#36 AnnotatorNotes T148 not a header but provides specific information for the interaction
T149    ContextualInformation 8036 8095 Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors
#37 AnnotatorNotes T149 not a header but provides specific information for the interaction
T150    ClinicalConsequencePK 8111 8210 Mean (SD) Noncompartmental Pharmacokinetic Parameters After Multiple Doses of 5 mg/day in Older Men
T151    ClinicalConsequencePK 8212 8281 Mean (SD) Pharmacokinetic Parameters in Healthy Young Subjects (n=15)
T152    ClinicalConsequencePK 8283 8294 Mean (± SD)
T153    DrugIndividual 8317 8329    Methotrexate
#38 AnnotatorNotes T153 not an actual header
T154    DrugGroup 8331 8344 Miscellaneous
#39 AnnotatorNotes T154 main heading with "drug name" and "effect" subheadings
T155    ManagementOption 8346 8352  NSAIDs
#40 AnnotatorNotes T155 not a heading but recommendations are given in the adjacent column
T156    DrugIndividual 8354 8382    Name of the Concomitant Drug
T157    Mechanism 8384 8412 Noted or anticipated Outcome
T158    DrugIndividual 8414 8432    OATP1B1 Inhibitors
#41 AnnotatorNotes T158 also explains the clinical impact and recommendations on use
T159    DrugIndividual 8434 8460    OATP1B1 and BCRP Substrate
#42 AnnotatorNotes T159 also explains the clinical impact and recommendations on use
T160    ManagementOption 8462 8485  Oral antidiabetic drugs
#43 AnnotatorNotes T160 not a heading but recommendations are given in the adjacent column
T161    DrugIndividual 8487 8497    Oral drugs
T162    DrugIndividual 8586 8596    Oral drugs
T163    DrugIndividual 8647 8657    Oral drugs
T164    DrugIndividual 8753 8763    Oral drugs
T165    DrugIndividual 8859 8869    Oral drugs
T166    DrugIndividual 8920 8930    Oral drugs
T167    DrugGroup 9077 9089 Other Agents
#44 AnnotatorNotes T167 also includes individual drugs
T168    DrugIndividual 9128 9159    Other Drugs/Dietary Supplements
T169    ManagementOption 9163 9189  Oxcarbazepine Dose(mg/day)
T170    ManagementOption 9191 9218  Prescribing Recommendations
T171    ManagementOption 9220 9247  Prescribing Recommendations
T172    ClinicalConsequenceOther 9355 9374  Radiographic Agents
#45 AnnotatorNotes T172 not a heading but the effect are given in the adjacent column
T173    ManagementOption 10075 10088    ecommendation
T174    ManagementOption 10090 10104    Recommendation
T175    ManagementOption 10116 10131    Recommendations
T176    ManagementOption 10221 10236    Recommendations
T177    ManagementOption 10419 10433    Recommendation
T178    ManagementOption 10452 10466    Recommendation
T179    ManagementOption 10486 10500    Recommendation
T180    DrugIndividual 10534 10548  Specific Drugs
T181    DrugIndividual 10550 10573  Specific Drugs Reported
T182    ManagementOption 10575 10592    Stavudine  Dosage
T183    DrugGroup 10594 10616   Strong CYP3A4 Inducers
#46 AnnotatorNotes T183 not a heading
T184    DrugGroup 10650 10674   Strong CYP3A4 Inhibitors
#47 AnnotatorNotes T184 not a heading
T185    DrugGroup 10715 10739   strong CYP2D6 inhibitors
#48 AnnotatorNotes T185 not a heading
T186    DrugGroup 10783 10807   Strong CYP3A4 inhibitors
#49 AnnotatorNotes T186 not a heading
T187    DrugGroup 11013 11037   Strong CYP3A4 inhibitors
#50 AnnotatorNotes T187 not a heading
T188    DrugGroup 11276 11292   Sympathomimetics
#51 AnnotatorNotes T188 not a heading
T189    ClinicalConsequencePK 11294 11315   TOPAMAX Concentration
T190    ClinicalConsequencePK 11317 11325   Tmax(hr)
T191    Mechanism 11431 11450   Type Of Interaction
T192    ContextualInformation 11473 11507   Vardenafil 10 mgPlacebo-subtracted
#52 AnnotatorNotes T192 refers to blood pressure outcome
T193    ContextualInformation 11509 11543   Vardenafil 20 mgPlacebo-subtracted
#53 AnnotatorNotes T193 refers to blood pressure outcome
T194    ClinicalConsequencePK 11615 11677   Voriconazole Plasma Exposure (Cmax and AUC? after 200 mg q12h)
T195    ContextualInformation 11865 11881   blood dyscrasias
T196    ContextualInformation 12160 12209   edema hereditary coumarin resistance hyperlipemia
T197    DrugIndividual 12263 12286  serum TBG concentration
#54 AnnotatorNotes T197 not a heading but drugs that may increase serum TBG concentration are listed
